Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 19.34% is 33% below its 5-year average of 28.69%, near the low end of its 5-year range (0.00%–100.00%).
19.31% above its 12-month average of 16.21%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 23.51%.
GROSS MARGIN
19.34%
GROSS MARGIN AVG TTM
16.21%
GROSS MARGIN AVG 3Y
46.34%
GROSS MARGIN AVG 5Y
28.69%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+19.31%
CURRENT VS 3Y AVG
-58.27%
CURRENT VS 5Y AVG
-32.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
-52.40%
vs the sector median at left
Bio Green Med Solution, Inc.
Market Cap
$4.64M
Gross Margin
19.34%
TTM Avg
16.21%
3Y Avg
46.34%
5Y Avg
28.69%
Market Cap
$4.58M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.53M
Gross Margin
26.32%
TTM Avg
-195.38%
3Y Avg
-178.16%
5Y Avg
-96.97%
Market Cap
$4.49M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.82M
Gross Margin
100.00%
TTM Avg
99.28%
3Y Avg
89.13%
5Y Avg
81.38%
Market Cap
$4.22M
Gross Margin
31.52%
TTM Avg
25.06%
3Y Avg
26.02%
5Y Avg
31.75%
Market Cap
$5.17M
Gross Margin
77.68%
TTM Avg
77.66%
3Y Avg
77.69%
5Y Avg
77.69%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio Green Med Solution, Inc. (BGMS) | $4.64M | 19.34% | 16.21% | 46.34% | 28.69% |
| CalciMedica, Inc. (CALC)vs › | $4.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.53M | 26.32% | -195.38% | -178.16% | -96.97% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.82M | 100.00% | 99.28% | 89.13% | 81.38% |
| Imunon, Inc. (IMNN)vs › | $5.04M | 0.00% | 0.00% | 25.00% | 50.00% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.22M | 31.52% | 25.06% | 26.02% | 31.75% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.17M | 77.68% | 77.66% | 77.69% | 77.69% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.17M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
19.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 23.51% |
| 2026-03-31 | 18.38% |
| 2025-12-31 | 18.17% |
| 2025-09-30 | 20.99% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 93.10% |
| 2023-12-31 | 74.19% |
| 2023-09-30 | 56.25% |
| 2023-06-30 | 97.86% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -661.33% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | -597.47% |
| 2016-09-30 | -1075.12% |
| 2016-06-30 | -1087.84% |
| 2016-03-31 | -1697.84% |
| 2015-12-31 | -507.13% |
| 2015-09-30 | -306.15% |
| 2015-06-30 | -771.62% |
| 2015-03-31 | -748.05% |
| 2014-12-31 | -1687.85% |
